Jyong Biotech Ltd. (MENS) Income Statement
MENS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsMENS revenue and net income
MENS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MENS quarterly EPS vs estimates
Jyong Biotech beat the analyst EPS estimate in 0 of the last 1 quarters.
MENS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $100,000 | $120,000 | $127,000 | $122,000 | $121,000 | — |
| Gross profit | −$100,000 | −$120,000 | −$127,000 | −$122,000 | −$121,000 | — |
| Research & development | $731,000 | $927,000 | $1.1M | $1.3M | $1.6M | $1.5M |
| Sales, general & admin | $1.8M | $1.1M | $1.7M | $1.5M | $845,000 | $931,000 |
| Total operating expenses | $2.5M | $2.1M | $2.8M | $2.8M | $2.4M | $2.4M |
| Operating income | −$2.6M | −$2.1M | −$2.8M | −$2.8M | −$2.4M | −$2.4M |
| Interest income | $610,000 | $7,000 | $56,000 | $5,000 | $6,000 | — |
| Interest expense | $2.5M | $1.0M | $757,000 | $765,000 | $835,000 | $832,000 |
| Income before taxes | −$4.7M | −$3.0M | −$4.4M | −$6.6M | −$4.2M | −$1.9M |
| Net income | −$4.7M | −$3.0M | −$4.4M | −$6.6M | −$4.2M | −$1.9M |
| EBITDA | −$2.5M | −$1.9M | −$3.5M | −$5.7M | −$3.2M | −$2.3M |
| EPS (diluted) | −$0.06 | −$42.16 | −$61.45 | — | — | — |
| Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | — | — | $58,000 | — | $62,000 | — | — |
| Gross profit | — | — | — | — | −$58,000 | — | −$62,000 | — | — |
| Research & development | $446,000 | $223 | $367,000 | $184 | $214 | $214 | $250 | $250 | $266 |
| Sales, general & admin | — | $672 | — | $224 | $338 | $338 | $226 | $226 | $578 |
| Total operating expenses | $1.8M | $896 | $816,000 | $408 | $552 | $552 | $476 | $476 | $844 |
| Operating income | −$1.8M | −$896 | −$816,000 | −$408 | −$552 | −$552 | −$476 | −$476 | −$844 |
| Interest expense | $2.1M | $768 | $417,000 | — | $587,000 | $293 | $448,000 | $221 | $172 |
| Income before taxes | −$3.4M | −$1,710 | −$1.3M | −$626 | −$846 | −$846 | −$663 | −$663 | −$1,329 |
| Net income | −$3.4M | −$1,710 | −$1.3M | −$626 | −$846 | −$846 | −$663 | −$663 | −$1,329 |
| EBITDA | −$1.8M | −$866 | −$835,000 | −$378 | −$524 | −$524 | −$444 | −$444 | −$813 |
| EPS (diluted) | — | — | — | −$0.02 | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MENS's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MENS financial results
Jyong Biotech reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $4.7 million. Diluted earnings per share came to −$0.06.
See the MENS stock overview for the latest quote and news, or the MENS chart for price history and technical indicators.
MENS income statement FAQ
Does Jyong Biotech have revenue?
Jyong Biotech reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Jyong Biotech profitable?
No. Jyong Biotech reported a net loss of $4.7 million in fiscal 2025.
How much does Jyong Biotech spend on research and development?
Jyong Biotech spent $0.7 million on research and development in fiscal 2025.
What are Jyong Biotech's earnings per share?
Jyong Biotech earned $-0.06 per diluted share in fiscal 2025, compared with $-42.16 a year earlier.
When does Jyong Biotech's fiscal year end?
Jyong Biotech's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.